{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-417384","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-10-08T10:28:19+00:00","discovered_at":"2026-10-08T10:30:00.288649+00:00","generated_at":"2026-10-12T15:40:25.828577+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perspective Therapeutics wins FDA Fast Track for PSV359 in FAP-positive solitary fibrous tumors","bullets":["FDA granted Fast Track Designation for [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs).","PSV359 is an investigational FAP-targeted alpha-particle therapy using the alpha-emitting isotope 212Pb, now in an ongoing Phase 1/2a study in advanced FAP-positive solid tumors.","Fast Track may bring more frequent FDA interactions and eligibility for rolling review, Accelerated Approval, or Priority Review if criteria are met.","CMO Markus Puhlmann noted no approved therapies specifically target FAP-alpha; imaging of FAP expression allows patient selection for targeted alpha therapy.","CEO Thijs Spoor called the designation an important step for the broader PSV359 program; SFT patients with unresectable/metastatic disease have limited options."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-417384","json":"https://secwatch.observer/filing/0001193125-26-417384.json","markdown":"https://secwatch.observer/filing/0001193125-26-417384.md","text":"https://secwatch.observer/filing/0001193125-26-417384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526417384/0001193125-26-417384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526417384/catx-20261008.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:40:25.828577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}